Laboratory Testing for Inflammatory Bowel Disease
Driving Healthcare Savings and Patient Outcomes

These products may not be cleared for use in your country. Please contact your sales representative for information about specific product availability.

Inflammatory bowel disease (IBD) is characterized by destructive inflammation of the intestinal tract with ulcerative colitis and Crohn’s disease as the most common disorders. Both diseases are life-long conditions with periods of remission and relapse.1

  • About 10 percent of IBD patients are misdiagnosed with irritable bowel syndrome (IBS) and in 3 percent of cases, this may persist for five or more years.2
  • The time to diagnose Crohn's disease from onset of symptoms takes, on average, nine months.3
  • An early diagnosis in IBD matters, as it is associated with improved patient outcomes and increased treatment success.3-6
  • Because of its 98 to 99 percent sensitivity for IBD, a negative EliA™ Calprotectin 2 test result helps to rule out IBD and thus differentiate between inflammatory and non-inflammatory bowel diseases, potentially avoid endoscopy, and reduce the associated patient risk.7,8

 

Why choose Thermo Fisher Scientific as your partner in IBD diagnostics?

 

Reducing avoidable invasive procedures.

The EliA™ IBD portfolio, comprising the EliA Calprotectin 2 and the EliA™ ASCA IgA and IgG tests (ASCA: anti-Saccharomyces cerevisiae antibodies), supports the identification and the differentiation of IBD.

The follow-up of a positive EliA Calprotectin 2 test result with EliA ASCA IgA and IgG tests and a p-ANCA indirect immunofluorescence assay (IFA) helps differentiate between Crohn’s disease and ulcerative colitis, potentially avoiding further investigations and providing guidance for endoscopic procedures.9,10

 

Results you can rely on.

The high sensitivity (98-99%) of the EliA Calprotectin 2 test, together with a negative predictive value (NPV) of 98.4 percent, make the test an outstanding tool helping to rule out inflammatory bowel disease.7,8

 

A test portfolio optimized to help differentiate between gastrointestinal diseases.

The EliA™ gastrointestinal portfolio* enables you to help rule in or rule out IBD (and subsequently differentiate between Crohn’s disease and ulcerative colitis), IBS, celiac disease, non-celiac gluten sensitivity, and wheat allergy.

The EliA gastrointestinal portfolio can be measured from one sample in one run and on the same fully automated Phadia™ Laboratory Systems.
*EliA Calprotectin 2, EliA ASCA IgA and IgG, EliATM Celikey IgA and IgG, EliATM GliadinDP IgA and IgG tests, ImmunoCAP™ Wheat allergen, f4

 

We have exciting news: the new stool extraction kit reducing manual steps by 50%!

To support the needs of our customers, the EliA™ Stool Extraction Kit plus extraction device (Art. No. 14-6665-01) for the EliA™ Calprotectin 2 test was developed to offer an optimized stool extraction procedure.

  • Fewer extraction steps: 8 steps reduced to 4
  • Enhanced safety: only one initial labeling step, decanting step has been removed 
  • Time savings: less hands-on and procedure time giving savings of 24%1
  • No software or systems update required

The EliA Stool Extraction Kit plus extraction device helps you to increase the overall efficiency in your laboratory. 

 

Total process time  
for extraction of 30 stool samples

EliATM Stool Extraction Kit 2

EliA Stool Extraction Kit plus

59 min 39 sec

45 min 33 sec

Reduction of 24%

Total hands-on time
for extraction of 30 stool samples

EliATM Stool Extraction Kit 2

EliA Stool Extraction Kit plus

44 min 39 sec

35 min 33 sec

Reduction of 20%

Benefits Brochure EliA™ Stool Extraction Kit Plus
EliA™ Stool Extraction Kit Plus Flyer
EliA™ Stool Extraction Kit Plus Video
Explore the full EliA portfolio.
View Portfolio
Find an instrument to run EliA tests.
View Phadia Laboratory Systems
Find helpful resources for your lab and your clients.
Visit Resource Library
References
  1. Torres, J, Burisch, J, Riddle, M, Dubinsky, M et al. Preclinical disease and preventive strategies in IBD: perspectives, challenges and opportunities. Gut 2016;65(7):1061-9.
  2. Card TR, Siffledeen J, Fleming KM. Are IBD patients more likely to have a prior diagnosis of irritable bowel syndrome? Report of a case-control study in the General Practice Research Database. United European Gastroenterol J. 2014;2(6):505-12.
  3. Vavricka SR, Spigaglia SM, Rogler G, Pittet V, Michetti P, Felley C, et al. Systematic evaluation of risk factors for diagnostic delay in inflammatory bowel disease. Inflamm Bowel Dis. 2012;18(3):496-505.
  4. Schoepfer AM, Dehlavi MA, Fournier N, Safroneeva E, Straumann A, Pittet V, et al. Diagnostic delay in Crohn's disease is associated with a complicated disease course and increased operation rate. Am J Gastroenterol. 2013;108(11):1744-53; quiz 54.
  5. Etchevers MJ, Aceituno M, Sans M. Are we giving azathioprine too late? The case for early immunomodulation in inflammatory bowel disease. World J Gastroenterol. 2008;14(36):5512-8.
  6. Markowitz J. Early inflammatory bowel disease: different treatment response to specific or all medications? Dig Dis. 2009;27(3):358-65.
  7. Wulandari A A, Schulz J, Hartmann F, Dignass A, Stein J. Poster No 119 presented at 11th Congress of ECCO, Amsterdam, Netherlands, 2016 e 48. 
  8. Thermo Fisher Scientific. Internal Study. 
  9. Bernstein CN, Fried M, Krabshuis JH, Cohen H, et. Al. World Gastroenterology Organization Practice Guidelines for the diagnosis and management of IBD in 2010. Inflamm Bowel Dis 2010;16(1):112-24.
  10. Mitsuyama, K, Niwa, M, Takedatsu, H, Yamasaki, H, et al. Antibody markers in the diagnosis of inflammatory bowel disease. World J Gastroenterol 2016; 22(3):1304-10.